Fundamental Data for INO

Inovio Biomedical Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electroporation technology. Its electrochemical tumor ablation therapy is designed to preserve healthy tissue, improve quality of life, and lower treatment costs compared to surgery.

# Employees: 37

Address: 11494 Sorrento Valley Road,San Diego,CA,USA

Phone: 858 597-6006

Fax: 858-597-0119

Website: www.inovio.com

Email: investor.relations@inovio.com

Sector: Medical

Industry: MED INSTRUMENTS

Executive Officers

Avtar Dhillon (Presi.; C.E.O.; Dir.)

Peter Kies (C.F.O.; Princ. Acctg. Off.)

Simon X. Benito (Dir.)

James L. Heppell (Dir.)

Tazdin Esmail (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 4/6/2010

Mean EPS (Next Qtr): ($0.05)

Mean EPS (Year): ($0.29)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 1

Shares Performance

Period	INO	Compare to S&P
YTD	169.23 %	122.80 %
4 Weeks	34.62 %	27.80 %
12 Weeks	-31.37 %	-36.09 %

Shares Information

Analyst Coverage: Y

Avg Volume: 1076816

Shares Outstanding: 101M

Market Cap: $0.14B

52 Week High: $3.18

52 Week Low: $0.19

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 9/13/2004 INO split by factor of 0.250

Earnings Performance

EPS Growth in Last Quarter: 50.00 %

EPS Growth in Last Year: 40.00 %

Sales Growth in Last Quarter: 46.31 %

Sales Growth in Last Quarter: 701.32 %

Financials

Qtr Book Value: $2.09

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 20.890